NU-6027
CAS No. 220036-08-8
NU-6027 ( NU6027;NU 6027 )
Catalog No. M13509 CAS No. 220036-08-8
NU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 34 | Get Quote |
|
5MG | 55 | Get Quote |
|
10MG | 91 | Get Quote |
|
25MG | 186 | Get Quote |
|
50MG | 295 | Get Quote |
|
100MG | 441 | Get Quote |
|
500MG | 981 | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNU-6027
-
NoteResearch use only, not for human use.
-
Brief DescriptionNU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively.
-
DescriptionNU-6027 (NU6027) is an ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 2.5 uM and 1.3 uM respectively; inhibits human tumor cells with a mean GI50 of 10 ±6 uM; also inhibits cellular ATR (IC50=6.7 uM) and RAD51 focus formation, increases the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy.
-
SynonymsNU6027;NU 6027
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorATR;CDK1;CDK2;DNA-PK
-
Research AreaOther Indications
-
Indication——
Chemical Information
-
CAS Number220036-08-8
-
Formula Weight251.30
-
Molecular FormulaC11H17N5O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 47 mg/mL (187 mM); Ethanol: 3 mg/mL (11.93 mM); Water: <1 mg/mL ( < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESNC1=NC(OCC2CCCCC2)=C(N=O)C(N)=N1
-
Chemical Name6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Arris CE, et al. J Med Chem. 2000 Jul 27;43(15):2797-804.
2. Peasland A, et al. Br J Cancer. 2011 Jul 26;105(3):372-81.
3. Boschi D, et al. Eur J Med Chem. 2013 Oct;68:333-8.
2. Peasland A, et al. Br J Cancer. 2011 Jul 26;105(3):372-81.
3. Boschi D, et al. Eur J Med Chem. 2013 Oct;68:333-8.
molnova catalog
related products
-
Dinaciclib
A potent and selective CDK inhibitor with IC50 of 1, 1, 3 and 4 nM against CDK2, CDK5, CDK1 and CDK9, respectively.
-
BAY 1251152
BAY 1251152 is the first potent, selective, orally available PTEFb/CDK9 inhibitor with biochemical IC50 of 9 nM and MOLM13 cell IC50 of 29 nM.
-
CDK4-IN-1
CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM.